VR23
|
- ₹0
- Product name: VR23
- CAS: 1624602-30-7
- MF: C19H16ClN5O6S
- MW: 477.88
- EINECS:
- MDL Number:MFCD28502093
- Synonyms:VR23;7-Chloro-4-[4-[(2,4-dinitrophenyl)sulfonyl]-1-piperazinyl]quinoline;VR23(VR-23);7-chloro-4-(4-((2,4-dinitrophenyl)sulfonyl)piperazin-1-yl)quinoline;CS-1579;Quinoline, 7-chloro-4-[4-[(2,4-dinitrophenyl)sulfonyl]-1-piperazinyl]-;VR23 >=98% (HPLC)
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
storage temp. :Store at -20°C
solubility :insoluble in EtOH; insoluble in H2O; ≥45.55 mg/mL in DMSO
form :Powder
color :Light yellow to yellow
solubility :insoluble in EtOH; insoluble in H2O; ≥45.55 mg/mL in DMSO
form :Powder
color :Light yellow to yellow
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
Description
VR23 is a chloroquine derivative that functions as a proteasome inhibitor (IC50s = 1 nM, 50-100 nM, and 3 μM for trypsin-like, chymotrypsin-like, and caspase-like proteasomes, respectively). It also deregulates the activity of cyclin E and other centrosomal proteins, resulting in the induction of multiple centrosome amplification, abnormal spindle formation, uneven cytokinesis, irreversible mitotic arrest, and eventually apoptosis that is specific to cancer cells. In combination with the chymotrypsin-like proteasome inhibitor bortezomib , VR23 can produce a synergistic effect in killing multiple myeloma cells, including those that are resistant to bortezomib.More related product prices
VS-5584